Our study showed a decrease in infarct volume, neurological deficit score, and lipid peroxidation by administration of a more specific 12/15-LOX inhibitor, ML351, at the acute and subacute phases of ischemic stroke in mice which was compatible with the previous studies using different 12/15-LOX inhibitors in mice ischemic stroke (Jin et al., 2008; Yigitkanli et al., 2013; Liu X. et al., 2017; Karatas et al., 2018). Here, LOX is linked to ischemic stroke.